Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15325124 | 0.84 | GDA (0.43) | POLBALOX15ALDH1A1TDP1ADORA3 | |
| SCHEMBL18658580 | 0.79 | GDA (0.39) | POLBALOX15ALDH1A1TDP1ADORA3 | |
| SCHEMBL4069622 | 0.79 | KMT2A (0.40) | POLBALOX15ALDH1A1TDP1ADORA3 | |
| SCHEMBL24802600 | 0.77 | ADORA3 (0.56) | POLBALOX15ALDH1A1TDP1ADORA3 | |
| SCHEMBL16466807 | 0.73 | KMT2A (0.36) | POLBALOX15ALDH1A1TDP1ADORA3 | |
| SCHEMBL18257489 | 0.72 | GDA (0.34) | POLBALOX15ALDH1A1TDP1ADORA3 | |
| SCHEMBL16488194 | 0.72 | KMT2A (0.36) | POLBALOX15ALDH1A1TDP1ADORA3 | |
| SCHEMBL16488189 | 0.72 | GDA (0.34) | POLBALOX15ALDH1A1TDP1ADORA3 | |
| SCHEMBL18658555 | 0.72 | KMT2A (0.36) | POLBALOX15ALDH1A1TDP1ADORA3 | |
| SCHEMBL15325115 | 0.72 | GDA (0.34) | POLBALOX15ALDH1A1TDP1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2837629-B1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | ASYMCHEM LABORATORIES (TIANJIN) CO LTD (CN) | 2017-03-22 | — | — | EP | disclosed |
| EP-2077268-A1 | Process for preparing inhibitors of nucleoside metabolism | Industrial Research Limited (NZ) | 2009-07-08 | — | — | EP | disclosed |
| EP-1165564-B1 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE METABOLISM | IND RES LTD (NZ) | 2009-03-11 | — | — | EP | disclosed |
| US-7405297-B2 | Process for preparing inhibitors of nucleoside metabolism | INDUSTRIAL RESEARCH LIMITED (NZ) | 2008-07-29 | — | — | US | disclosed |
| US-20070161667-A1 | Process for preparing inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-7211677-B2 | Process for preparing inhibitors of nucleoside metabolism | INDUSTRIAL RESEARCH LIMITED (NZ) | 2007-05-01 | — | — | US | disclosed |
| US-20060089498-A1 | Process for preparing inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| US-7022852-B2 | Process for preparing inhibitors of nucleoside metabolism | INDUSTRIAL RESEARCH LIMITED (NZ) | 2006-04-04 | — | — | US | disclosed |
| US-20040181063-A1 | Process for preparing inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | disclosed |
| US-6693193-B1 | COUPLING AN N- AND O-PROTECTED 2,3-DIHYDROXY-PYRROLIDINE TO THE 2-POSITION AND DEPROTECTING | INDUSTRIAL RESEARCH LIMITED (NZ) | 2004-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089498-A1 | Process for preparing inhibitors of nucleoside metabolism | UGT1A3, AGL, PNP | POLB 217/4885ALOX15 3821/4885ALDH1A1 2979/4885 |
| US-20040181063-A1 | Process for preparing inhibitors of nucleoside metabolism | XDH, PNP, AGL | POLB 345/4885ALOX15 2366/4885ALDH1A1 1853/4885 |
| US-20070161667-A1 | Process for preparing inhibitors of nucleoside metabolism | PNP, UGT1A3, AGL | POLB 157/4885ALOX15 3452/4885ALDH1A1 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.